Mariko Hakoshima

1.3k total citations · 1 hit paper
44 papers, 795 citations indexed

About

Mariko Hakoshima is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Mariko Hakoshima has authored 44 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 17 papers in Molecular Biology. Recurrent topics in Mariko Hakoshima's work include Metabolism, Diabetes, and Cancer (14 papers), Diabetes Treatment and Management (13 papers) and Liver Disease Diagnosis and Treatment (10 papers). Mariko Hakoshima is often cited by papers focused on Metabolism, Diabetes, and Cancer (14 papers), Diabetes Treatment and Management (13 papers) and Liver Disease Diagnosis and Treatment (10 papers). Mariko Hakoshima collaborates with scholars based in Japan and United States. Mariko Hakoshima's co-authors include Hidekatsu Yanai, Hisayuki Katsuyama, Hiroki Adachi, Akiko Kawaguchi, Akahito Sako, Hidetaka Hamasaki, Sachiyo Yoshio, Masatoshi Imamura, Yoshihiko Aoki and Taiji Yamazoe and has published in prestigious journals such as International Journal of Molecular Sciences, Molecules and Cells.

In The Last Decade

Mariko Hakoshima

43 papers receiving 780 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease

2021 337 citations Hidekatsu Yanai, Hiroki Adachi et al. International Journal of Molecular Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mariko Hakoshima Japan	12	304	268	214	208	174	44	795
Hiroki Adachi Japan	16	414 1.4×	335 1.3×	293 1.4×	238 1.1×	210 1.2×	74	1.1k
Sirirat Reungjui Thailand	17	369 1.2×	341 1.3×	223 1.0×	288 1.4×	155 0.9×	23	1.1k
Sung Kweon Cho South Korea	14	290 1.0×	85 0.3×	193 0.9×	104 0.5×	148 0.9×	31	661
Mohamed Shafiu United States	5	506 1.7×	515 1.9×	229 1.1×	432 2.1×	131 0.8×	7	1.1k
Yoshifuru Tamura Japan	19	532 1.8×	93 0.3×	278 1.3×	72 0.3×	189 1.1×	62	931
Hadi Tabibi Iran	20	245 0.8×	114 0.4×	116 0.5×	77 0.4×	87 0.5×	54	861
Magdalena Cristóbal-García Mexico	9	334 1.1×	86 0.3×	264 1.2×	90 0.4×	116 0.7×	10	717
E. Ritz Germany	8	556 1.8×	225 0.8×	172 0.8×	85 0.4×	242 1.4×	9	1.1k
Liheng Guo China	18	179 0.6×	77 0.3×	191 0.9×	178 0.9×	141 0.8×	49	891
Zhi Guo China	12	195 0.6×	144 0.5×	175 0.8×	95 0.5×	107 0.6×	24	874

Countries citing papers authored by Mariko Hakoshima

Since Specialization

Citations

This map shows the geographic impact of Mariko Hakoshima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariko Hakoshima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariko Hakoshima more than expected).

Fields of papers citing papers by Mariko Hakoshima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariko Hakoshima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariko Hakoshima. The network helps show where Mariko Hakoshima may publish in the future.

Co-authorship network of co-authors of Mariko Hakoshima

This figure shows the co-authorship network connecting the top 25 collaborators of Mariko Hakoshima. A scholar is included among the top collaborators of Mariko Hakoshima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mariko Hakoshima. Mariko Hakoshima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yanai, Hidekatsu, Hiroki Adachi, Mariko Hakoshima, & Hisayuki Katsuyama. (2024). Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes. Molecules. 29(24). 5936–5936. 3 indexed citations

Katsuyama, Hisayuki, et al.. (2024). Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients. Journal of Clinical Medicine. 13(16). 4929–4929. 1 indexed citations

Yanai, Hidekatsu, et al.. (2024). A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease. Cells. 13(5). 450–450. 13 indexed citations

Hakoshima, Mariko, Hisayuki Katsuyama, Hidekatsu Yanai, et al.. (2024). Association between comorbidities associated with diabetes and higher-level functional status in older patients with type 2 diabetes mellitus: a cross sectional study. European Geriatric Medicine. 15(4). 1101–1110. 2 indexed citations

Katsuyama, Hisayuki, et al.. (2024). Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan. Diabetes Research and Clinical Practice. 213. 111752–111752. 4 indexed citations

Hakoshima, Mariko, et al.. (2023). Clinical, Hematological, Biochemical and Radiological Characteristics for Patients With Splenic Infarction: Case Series With Literature Review. Journal of Clinical Medicine Research. 15(1). 38–50. 6 indexed citations

Kakazu, Eiji, Hisayuki Katsuyama, Mariko Hakoshima, et al.. (2023). Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease. Hepatology Research. 53(7). 618–628. 8 indexed citations

Yanai, Hidekatsu, Hiroki Adachi, Mariko Hakoshima, & Hisayuki Katsuyama. (2023). Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. International Journal of Molecular Sciences. 24(18). 13942–13942. 25 indexed citations

Yanai, Hidekatsu, Hiroki Adachi, Mariko Hakoshima, & Hisayuki Katsuyama. (2023). Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications. Biology. 12(5). 726–726. 13 indexed citations

10.

Yanai, Hidekatsu, Hisayuki Katsuyama, Mariko Hakoshima, & Hiroki Adachi. (2023). Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study. Biomedicines. 11(2). 567–567. 10 indexed citations

11.

Yanai, Hidekatsu, Hiroki Adachi, Mariko Hakoshima, & Hisayuki Katsuyama. (2023). A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad. Cardiology Research. 14(2). 158–160.

12.

Katsuyama, Hisayuki, Hidekatsu Yanai, Hiroki Adachi, & Mariko Hakoshima. (2023). A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia. Gastroenterology Research. 16(4). 240–243. 5 indexed citations

13.

Yanai, Hidekatsu, Hisayuki Katsuyama, & Mariko Hakoshima. (2021). A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients. Cardiology Research. 12(6). 358–362. 6 indexed citations

14.

Katsuyama, Hisayuki, et al.. (2020). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes: A Chart-Based Analysis. Journal of Endocrinology and Metabolism. 10(1). 1–7. 3 indexed citations

15.

Yanai, Hidekatsu, Mariko Hakoshima, & Hisayuki Katsuyama. (2019). Clinical, Biochemical, Hematological, Endocrinological and Immunological Differences Between Graves’ Disease Patients With and Without Thyroid Storm. Journal of Clinical Medicine Research. 11(6). 452–457. 6 indexed citations

16.

Yanai, Hidekatsu, Hiroki Adachi, Hisayuki Katsuyama, et al.. (2018). Exercise Therapy for Patients With Type 2 Diabetes: A Narrative Review. Journal of Clinical Medicine Research. 10(5). 365–369. 30 indexed citations

17.

Yanai, Hidekatsu, Mariko Hakoshima, & Hiroki Adachi. (2018). Which Factor Determines the Duration Required for Relief of Glucotoxicity by the Intensive Insulin Therapy?. Journal of Clinical Medicine Research. 10(7). 606–608. 2 indexed citations

18.

Sugimoto, Takayuki, Mariko Hakoshima, Hidetaka Hamasaki, & Hidekatsu Yanai. (2017). Abdominal Abscess due to Perforation of the Terminal Ieum Caused by a Fish Bone Treated by the Conservative Treatment Using Antibiotics. Journal of Medical Cases. 8(11). 361–364. 1 indexed citations

19.

Yanai, Hidekatsu, Mariko Hakoshima, Hiroki Adachi, et al.. (2017). Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data. Journal of Clinical Medicine Research. 9(7). 605–612. 24 indexed citations

20.

Yanai, Hidekatsu, Mariko Hakoshima, & Hiroki Adachi. (2017). What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?. Journal of Clinical Medicine Research. 9(5). 446–448. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact